Home
 »  News
 »  Researchers Identify Target To Prevent Hardening Of Arteries
Veins1 Headlines

Researchers Identify Target To Prevent Hardening Of Arteries

Printer Friendly Version     Email this Article     Links/Reprints

hardening

Researchers Identify Target To Prevent Hardening Of Arteries

May 21, 2013
Source: Sanford-Burnham Medical Research Institute

The hardening of arteries is a hallmark of atherosclerosis
, an often deadly disease in which plaques, excessive connective tissue, and other changes build up inside vessel walls and squeeze off the flow of oxygen-rich blood throughout the body. Now, researchers at Sanford-Burnham Medical Research Institute have described the molecular and cellular pathway that leads to this hardening of the arteries - and zeroed in on a particularly destructive protein called Dkk1. 

Their study was published online today by Arteriosclerosis, Thrombosis, and Vascular Biology. The findings suggest that the development of drug therapies to selectively inhibit endothelial Dkk1 signaling may help limit arteriosclerotic disease. 

"I think the strategy going forward is to find ways to modulate or inhibit Dkk1 function, but we're going to have to do it in a time-sensitive and cell type- specific fashion," said Dwight A. Towler, M.D., Ph.D., director of Sanford-Burnham's Cardiovascular Pathobiology Program and senior author of the study. "In diseases such as chronic renal deficiency or diabetes, where unregulated Dkk1 signaling can be destructive, it may be appropriate to restrain the action of Dkk1 for a prolonged period of time," Towler added. 

When the inflammatory response goes awry 

The Dkk1 protein, when functioning normally, is important for aiding in wound repair. But inflammatory responses triggered inside artery walls after the onset of hyperglycemia, and other metabolic injuries associated with diseases like diabetes, can trigger prolonged and destructive Dkk1 signaling. 

Dkk1 triggers the conversion of cells that line the interior surface of artery walls, called endothelial cells, into mesenchymal cells, which can direct connective tissue formation. This process is known as the endothelial-mesenchymal transition. The resulting fibrosis inside arterial walls leads to a dangerous stiffening of vessels that increases systolic blood pressure and ultimately impairs distal blood flow. 

Drug therapy strategies to target Dkk1 

Drug therapies should focus on the places where Dkk1 inhibition is called for - the arteries, in the case of atherosclerosis - because healthy Dkk1 signaling regulates normal processes such as cartilage and joint remodeling. To enable this targeted approach, Towler said he hopes to develop a therapeutic drug that would include a Dkk1 inhibitor and a peptide - a short chain of amino acids - engineered to target specific vascular tissues. 

Longtime Sanford-Burnham researcher and past president Erkki Ruoslahti, M.D., Ph.D., developed these homing peptides, which have been used to deliver cancer drugs to where they're most needed. "If we can target a Dkk1 antagonist to endothelial cells using the Ruoslahti peptides - or a similar strategy - that would be very, very powerful," Towler said. 

Dkk1 is from a family of molecules that arose during the development of vertebrates and is involved in heart formation in embryos. Researchers initially thought the protein's only role was to inhibit a molecular pathway known as canonical Wnt signaling, which controls cell differentiation. However, these new data identify surprising "cross-talk" between Dkk1 and a bone-inducing pathway previously shown to promote the endothelial-mesenchymal transition. 

Towler and his team will continue to study Dkk1 and Wnt signaling to identify potential drug targets to prevent the hardening of arteries in patients with atherosclerosis. 

Discuss in the Veins1 forums

Photo: Lara 

Previous Stories

Binge Drinking in College Can Lead to Heart Disease Later in Life

Mummies Study Reveals That Hardening Of The Arteries May Have Been A Global Problem In The Ancient World

People with Asthma at Increased Risk of Pulmonary Embolism

more Feature Stories

Comments

  • Add Comment

  • RSS
     
    This locator will help you to find vascular specialists in your area
     
    Postal or Zip Code
     
    Spider Vein Treatment
    By Haleigh

    Posted: Jul 15, 2017
     I have more spider veins and varicose veins too.I got pain some times and used enorid serum for 2 weeks.It reduces my spider veins with regular applicatin.Its not greasy and smells great.

    more more Forums Create a Topic
     
    Dr. Timur Sarac

    Dr. Timur Sarac:

    Developing Bioabsorbable Stents for Soldiers
      more
      more Heroes
      nominate a Hero
      Hero policy
    Home | About Us | Press | Make a Suggestion | Content Syndication | Terms of Service | Editorial Policy | Privacy Policy
    Last updated: Aug 18, 2017  © 2017 Body1 All rights reserved.